Draft Evidence Review: Ovarian Cancer: Screening - US Preventive Services Task Force

Draft Evidence Review: Ovarian Cancer: Screening - US Preventive Services Task Force





The U.S. Preventive Services Task Force is seeking public comments on a draft recommendation statement and draft evidence review on screening for ovarian cancer. After reviewing the evidence, the Task Force recommends against screening for ovarian cancer in women who are asymptomatic or show no symptoms. Both the draft recommendation statement and draft evidence review are available for review and public comment through August 14, 2017.

Draft Recommendation Statement: Ovarian Cancer: Screening - US Preventive Services Task Force

Draft Recommendation Statement: Ovarian Cancer: Screening - US Preventive Services Task Force







The U.S. Preventive Services Task Force is seeking public comments on a draft recommendation statement and draft evidence review on screening for ovarian cancer. After reviewing the evidence, the Task Force recommends against screening for ovarian cancer in women who are asymptomatic or show no symptoms. Both the draft recommendation statement and draft evidence review are available for review and public comment through August 14, 2017.

Announcing the Parkinson's Advocacy Toolkit

As people in the Parkinson' s community know, you can -- and often must -- be your own best advocate. Our new Parkinson's Advocacy Toolkit can help you take part in the public policy process and speak up for your needs.

   
The toolkit provides:

• Information on current policy issues, including health care reform and research funding,
• Tips on building relationships with members of Congress and educating them on what is fundamentally important to people with Parkinson's and their loved ones, and
• Best practices for using social
  and traditional media to advocate.

P.S. This August, Congress will break for its annual recess and lawmakers will head to their home states to meet with constituents. Use the toolkit to get involved!

U.S. Government/PEPFAR's Global Commitment to HIV/AIDS Remains Strong | HIV.gov

U.S. Government/PEPFAR's Global Commitment to HIV/AIDS Remains Strong | HIV.gov

U.S. Government/ PEPFAR's Global Commitment to HIV/AIDS Remains Strong

July 24, 2017 - Crossposted from PEPFAR Press Room

TOPICS: DOS, PEPFAR

Next week, thousands of scientists, activists, implementers, and leaders from around the world will convene at the 9th International AIDS Society Conference on HIV Science in Paris, France. This is a historic moment in the global HIV/AIDS response. The Trump Administration remains committed to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to not only save lives, but to also change the very course of the HIV pandemic....[READ MORE]

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses | HIV.gov

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses | HIV.gov

Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses

July 24, 2017 - Crossposted from NIAID Newsroom

TOPICS: NIAID, NIH, Research, Vaccine

Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate...[READ MORE]

Child Living with HIV Maintains Remission Without Drugs Since 2008 | HIV.gov

Child Living with HIV Maintains Remission Without Drugs Since 2008 | HIV.gov

Child Living with HIV Maintains Remission Without Drugs Since 2008

July 24, 2017 - Crossposted from NIAID Newsroom

TOPICS: NIAID, NIH, Research

A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. Previously, the “Mississippi Baby,” born with HIV in 2010, received anti-HIV treatment beginning 30 hours after birth, stopped therapy...[READ MORE]

Drug Interaction Concerns May Negatively Affect HIV Treatment Adherence Among Transgender Women | HIV.gov

Drug Interaction Concerns May Negatively Affect HIV Treatment Adherence Among Transgender Women | HIV.gov

Drug Interaction Concerns May Negatively Affect HIV Treatment Adherence Among Transgender Women

July 24, 2017 - Crossposted from NIAID Newsroom

TOPICS: NIAID, NIH, Research, Transgender, Treatment

Transgender women—people whose birth certificates indicate or once indicated male sex but who identify as women—are at high risk of HIV acquisition, and thus are a key population for HIV prevention and treatment efforts. A new study by researchers supported by the National Institutes of Health and Gilead Sciences reveals that among transgender women in Los Angeles, more than half of those living with HIV were concerned...[READ MORE]